A randomized trial of intravenous and oral iron in chronic kidney disease

Kidney International

Volumn 88, Issue 4, 2015, Pages 905-914

  Agarwal, Rajiv ^a   Kusek, John W ^b   Pappas, Maria K ^a  

^a INDIANA UNIVERSITY   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

adverse effects; anemia; chronic kidney disease; iron; randomized controlled trial

Indexed keywords

FERROUS SULFATE; HEMOGLOBIN; IRON SACCHARATE; ANTIANEMIC AGENT; BIOLOGICAL MARKER; FERRIC ION; FERRIC OXIDE, SACCHARATED; FERROUS ION; SACCHARIC ACID;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMOGLOBIN DETERMINATION; HOSPITALIZATION; HUMAN; INFECTION; IRON DEFICIENCY ANEMIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ANEMIA, IRON-DEFICIENCY; BLOOD; COMPARATIVE STUDY; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; EARLY TERMINATION OF CLINICAL TRIAL; INDIANA; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; AGED; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; DISEASE PROGRESSION; EARLY TERMINATION OF CLINICAL TRIALS; FEMALE; FERRIC COMPOUNDS; FERROUS COMPOUNDS; GLOMERULAR FILTRATION RATE; GLUCARIC ACID; HEMATINICS; HEMOGLOBINS; HUMANS; INDIANA; KIDNEY; MALE; MIDDLE AGED; QUALITY OF LIFE; RENAL INSUFFICIENCY, CHRONIC; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84942990469     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.163     Document Type: Article

References (34)

1. Coresh J, Wei GL, McQuillan G et al. Prevalence of high blood pressure and elevated serum creatinine level in the United States: findings from the third National Health and Nutrition Examination Survey (1988-1994). Arch Intern Med 2001; 161: 1207-1216.
2. Fishbane S, Pollack S, Feldman HI. Iron indices in chronic kidney disease in the National Health and Nutritional Examination Survey 1988-2004. Clin J Am Soc Nephrol 2009; 4: 57-61.
3. Nissenson AR, Strobos J. Iron deficiency in patients with renal failure. Kidney Int Suppl 1999; 69: S18-S21.
4. Besarab A. Iron and cardiac disease in the end-stage renal disease setting. Am J Kidney Dis 1999; 34: S18-S24.
5. Besarab A, Frinak S, Yee J. An indistinct balance: the safety and efficacy of parenteral iron therapy. J Am Soc Nephrol 1999; 10: 2029-2043.
6. Albaramki J, Hodson EM, Craig JC et al. Parenteral versus oral iron therapy for adults and children with chronic kidney disease. Cochrane Database Syst Rev 2012; 1: CD007857.
7. Haugen E, Nath KA. The involvement of oxidative stress in the progression of renal injury. Blood Purif 1999; 17: 58-65.
8. Klahr S. Oxygen radicals and renal diseases. Miner Electrolyte Metab 1997; 23: 140-143.
9. Agarwal R, Warnock D. Issues related to iron replacement in chronic kidney disease. Semin Nephrol 2002; 22: 479-487.
10. Zager RA, Johnson AC, Hanson SY et al. Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002; 40: 90-103.
11. Shah SV. Role of iron in progressive renal disease. Am J Kidney Dis 2001; 37: S30-S33.
12. Handelman GJ, Walter MF, Adhikarla R et al. Elevated plasma F2-isoprostanes in patients on long-term hemodialysis. Kidney Int 2001; 59: 1960-1966.
13. Spittle MA, Hoenich NA, Handelman GJ et al. Oxidative stress and inflammation in hemodialysis patients. Am J Kidney Dis 2001; 38: 1408-1413.
14. Salahudeen AK, Oliver B, Bower JD et al. Increase in plasma esterified F2-isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001; 60: 1525-1531.
15. Agarwal R, Vasavada N, Sachs NG et al. Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004; 65: 2279-2289.
16. Agarwal R, Leehey DJ, Olsen SM et al. Proteinuria induced by parenteral iron in chronic kidney disease-a comparative randomized controlled trial. Clin J Am Soc Nephrol 2011; 6: 114-121.
17. Drueke T, Witko-Sarsat V, Massy Z et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation 2002; 106: 2212-2217.
18. Becker BN, Himmelfarb J, Henrich WL et al. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8: 475-486.
19. Kidney Disease Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279-335.
20. Rozen-Zvi B, Gafter-Gvili A, Paul M et al. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis 2008; 52: 897-906.
21. Stoves J, Inglis H, Newstead CG. A randomized study of oral vs intravenous iron supplementation in patients with progressive renal insufficiency treated with erythropoietin. Nephrol Dial Transplant 2001; 16: 967-974.
22. Macdougall IC, Bock AH, Carrera F et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant 2014; 29: 2075-2084.
23. Parkkinen J, von Bonsdorff L, Peltonen S et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i. v. iron-saccharate administration. Nephrol Dial Transplant 2000; 15: 1827-1834.
24. Zager RA, Johnson AC, Hanson SY. Parenteral iron therapy exacerbates experimental sepsis. Rapid communication. Kidney Int 2004; 65: 2108-2112.
25. Zager RA, Johnson AC, Hanson SY et al. Parenteral iron compounds sensitize mice to injury-initiated TNF-alpha mRNA production and TNF-alpha release. Am J Physiol Renal Physiol 2005; 288: F290-F297.
26. Sengoelge G, Kletzmayr J, Ferrara I et al. Impairment of transendothelial leukocyte migration by iron complexes. J Am Soc Nephrol 2003; 14: 2639-2644.
27. Zheng H, Huang X, Zhang Q et al. Iron sucrose augments homocysteineinduced endothelial dysfunction in normal subjects. Kidney Int 2006; 69: 679-684.
28. Anker SD, Comin CJ, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448.
29. Ponikowski P, van Veldhuisen DJ, Comin-Colet J et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2014.
30. Miskulin DC, Zhou J, Tangri N et al. Trends in anemia management in US hemodialysis patients 2004-2010. BMC Nephrol 2013; 14: 264.
31. Brookhart MA, Schneeweiss S, Avorn J et al. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA 2010; 303: 857-864.
32. Levey AS, Coresh J, Greene T et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 2006; 145: 247-254.
33. Agarwal R, Vasavada N, Chase SD. Liquid chromatography for iothalamate in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 785: 345-352.
34. Hays RD, Kallich JD, Mapes DL et al. Development of the kidney disease quality of life (KDQOL) instrument. Qual Life Res 1994; 3: 329-338.